<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162721</url>
  </required_header>
  <id_info>
    <org_study_id>SARC-GYN1</org_study_id>
    <nct_id>NCT00162721</nct_id>
  </id_info>
  <brief_title>The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas</brief_title>
  <official_title>Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III study about the effects of the addition of polychemotherapy to adjuvant
      radiotherapy in the treatment of non-metastatic uterine sarcomas.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of the addition of an adjuvant chemotherapy to adjuvant pelvic radiotherapy on a 3 year event-free survival in the treatment of localized uterine sarcomas</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of the addition of an adjuvant chemotherapy to adjuvant pelvic radiotherapy on overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global toxicity of the treatment in each arm</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Uterine Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, ifosfamide, cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed uterine sarcoma (rereading in reference centers)

          -  Leiomyosarcoma, adenosarcoma, carcinosarcoma and high grade endometrial stromal
             sarcoma

          -  All stages &lt;= stage III (FIGO modified for endometrial carcinoma)

          -  Full surgical exeresis

          -  Age &gt;= 18 years and physiological age &lt;= 65 years

          -  Negative extension check-up (thoracic and abdomino-pelvic TDM)

          -  Performance status (PS) &lt;= 2 (ECOG)

          -  Normal haematologic functions (absolute neutrophil count &gt; 1,500/mm3, platelets &gt;
             100,000/mm3)

          -  Serum creatinine &lt; 1.25 x ULN

          -  Good hepatic check-up (total serum bilirubin &lt; 1.5 x ULN; AST or ALT &lt; 2.5 x ULN)

          -  Absence of neuropathy &gt; grade 1

          -  Left ventricular ejection fraction &gt; 50% (by isotopic or ultrasound scan
             determination)

          -  Written informed consent

        Exclusion Criteria:

          -  Low grade endometrial stromal sarcoma

          -  Time since surgery &gt; 8 weeks

          -  Specific contraindications to the studied treatment (cardiac, kidney, or hepatic ones)

          -  Antecedents or evolutive psychiatric disorder

          -  Concurrent active infection or other serious uncontrolled systemic disease

          -  Antecedents of cancer but a cutaneous basocellular one or an in situ epithelioma of
             the cervix
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Pautier, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Pautier, Dr</last_name>
    <phone>33 1 42 11 4340</phone>
    <email>pautier@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie Rey</last_name>
    <phone>33 1 42 11 4137</phone>
    <email>rey@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pautier, Dr</last_name>
      <phone>33 1 42 11 4340</phone>
      <email>pautier@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>August 9, 2007</last_update_submitted>
  <last_update_submitted_qc>August 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2007</last_update_posted>
  <keyword>Uterine sarcoma non metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

